Summit Therapeutics (NASDAQ:SMMT) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Summit Therapeutics (NASDAQ:SMMTGet Rating) in a research note released on Thursday. The firm issued a sell rating on the stock.

Summit Therapeutics stock opened at $1.12 on Thursday. The stock has a 50-day moving average of $2.41 and a two-hundred day moving average of $3.19. Summit Therapeutics has a one year low of $1.11 and a one year high of $8.70. The stock has a market cap of $109.90 million, a PE ratio of -1.17 and a beta of 0.99.

Summit Therapeutics (NASDAQ:SMMTGet Rating) last announced its quarterly earnings data on Thursday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter. Summit Therapeutics had a negative return on equity of 95.94% and a negative net margin of 493.14%. The firm had revenue of $4.84 million during the quarter.

Large investors have recently made changes to their positions in the company. Vance Wealth Inc. purchased a new position in shares of Summit Therapeutics in the fourth quarter worth about $33,000. Virtu Financial LLC purchased a new position in shares of Summit Therapeutics in the fourth quarter worth about $37,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Summit Therapeutics in the fourth quarter worth about $46,000. Bank of America Corp DE raised its stake in shares of Summit Therapeutics by 68.0% in the fourth quarter. Bank of America Corp DE now owns 19,311 shares of the company’s stock worth $52,000 after purchasing an additional 7,818 shares during the last quarter. Finally, Advisor Group Holdings Inc. raised its position in Summit Therapeutics by 85.3% during the third quarter. Advisor Group Holdings Inc. now owns 11,080 shares of the company’s stock valued at $56,000 after acquiring an additional 5,100 shares in the last quarter. Hedge funds and other institutional investors own 11.33% of the company’s stock.

Summit Therapeutics Company Profile (Get Rating)

Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.

Further Reading

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.